Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false and misleading statements regarding its business performance and financial guidance during the Class Period from November 7, 2024, to July 8, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [5]. - Defendants allegedly overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [5]. - The misleading statements made by the defendants about RxSight's business operations and prospects caused investors to suffer damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased RxSight securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Flywire Corporation (“Flywire” or the “Company”) (NASDAQ: FLYW) between February 28, 2024 and February 25, 2025, inclusive. For more information, submit a form at Flywire Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. following a significant drop in stock price after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [3][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1] - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4] Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives violated federal securities laws by making false or misleading statements regarding the IGNYTE trial's prospects [5] - It is claimed that the defendants overstated the trial's prospects, leading to the FDA deeming it inadequate and not well-controlled [5][6] - Following the FDA's announcement, Replimune's stock plummeted over 73% during intraday trading on July 22, 2025 [7] Group 3: Company Communication - On July 22, 2025, Replimune announced it received a Complete Response Letter from the FDA, indicating that the application could not be approved in its current form [6] - The FDA's response highlighted that the IGNYTE trial did not provide substantial evidence of effectiveness [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Centene common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by September 8, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Specifics - The lawsuit alleges that Centene's defendants provided misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [4] - Positive statements about Centene's enrollment and morbidity rates were made while concealing material adverse facts about the true state of these metrics [4]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38% from $12.79 to $7.95 per share [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose sales declines due to adoption challenges and structural issues [1][2]. Group 1 - The lawsuit represents investors who purchased or acquired RxSight's securities between November 7, 2024, and July 8, 2025 [1]. - Defendants are accused of not disclosing significant challenges that affected the company's sales performance [2]. - The deadline to file as a lead plaintiff in the class action is September 22, 2025 [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's lead product candidate, PGN-EDO51 [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's management made materially false and misleading statements about PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating PGN-EDO51's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Capricor Therapeutics, Inc. for alleged misrepresentations regarding the safety and efficacy data of its lead drug candidate, deramiocel, during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025 [1]. - The allegations focus on misrepresentations related to the four-year safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy [2]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file necessary documents by September 15, 2025, with the role involving representation of other class members in the litigation [3]. - Participation as a class member does not require serving as lead plaintiff, and all legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit highlights that the defendants concealed the importance of Organon's debt reduction strategy following its acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit claims that investors suffered damages once the true details about the company's financial priorities were revealed [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and misled investors about the company's operations and prospects [5]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, citing Hims' failure to comply with legal standards and the promotion of unsafe compounded drugs [6]. - Following the announcement, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant losses for investors [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].